RecruitMe Clinical Trial

A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)
Eribulin Mesylate in Pediatric Subjects with Rhabdomyosarcoma (RMS), non-Rhabdomyosarcoma Soft Tissue Sarcoma(NRSTS) and Ewing Sarcoma(EWS)
Sponsor:Eisai
Enrolling:Male and Female Patients
Age Range:Between 1 and 18 years old
IRB Number:AAAS0709
U.S. Government ID:NCT03441360
Contact: Rebecca Zylber, CPNP: 212-305-7212 / rjv2107@cumc.columbia.edu
Additional Study Information:

The main purpose of this study is to see if eribulin might work and might be used in the treatment of pediatric subjects with rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS) that has either come back or has not responded to the standard therapy. Eribulin will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle.

Do You Qualify?
Is your child 12 months to less than 18 years of age?YesNo
Does your child have relapsed or refractory RMS, NRSTS, or relapsed or refractory EWS?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Rebecca Zylber, CPNP
Email: rjv2107@cumc.columbia.edu
Phone: 212-305-7212